Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Mismatch Repair

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...

Mismatch Repair

Mismatch Repair

Principles of Pharmacogenetics: Types of Genetic Variants

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A novel framework for integrating post-mortem images with 3D body models for automatic injury medical documentation.

Journal of forensic and legal medicine·2026

Same author

[Out-of-hospital death confirmation algorithm].

Archiwum medycyny sadowej i kryminologii·2026

Same author

Methoxy topology controls potency and erythrocyte compatibility of 4'-hydroxychalcones: Integrated profiling in two lymphoma-derived cell lines, PBMCs, hemoglobin, and red blood cells.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026

Same author

Tension in transverse structures in women with pelvic organ prolapse - Preliminary observations.

Women's health (London, England)·2026

Same author

Clozapine levels in inpatients with schizophrenia are not a predictor of rehospitalization: a naturalistic retrospective study.

Pharmacological reports : PR·2026

Same author

Gaps and paths forward in cancer pharmacology and translational research.

Frontiers in pharmacology·2026

Search research articles

Related Experiment Video

Updated: May 18, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

No association between MTHFR C677T polymorphism and completed suicide.

Izabela Chojnicka¹, Agnieszka Sobczyk-Kopcioł, Marcin Fudalej

¹Department of Medical Genetics, Medical University of Warsaw, Poland.

|September 18, 2012

Summary

The MTHFR C677T gene variant (rs1801133) is not linked to completed suicide risk. This study found no significant association between the MTHFR 677T allele or TT genotype and suicide in a Polish population.

Related Experiment Videos

Last Updated: May 18, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Area of Science:

Genetics
Psychiatry
Forensic Science

Background:

The methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism (rs1801133) is implicated in various psychiatric disorders.
Previous research has not investigated the association between the MTHFR C677T polymorphism and completed suicide.

Purpose of the Study:

To determine if the MTHFR C677T polymorphism (rs1801133) is a risk factor for completed suicide.
To explore potential associations between this polymorphism and demographic/toxicological factors in suicide victims.

Main Methods:

Genotyping of the MTHFR C677T polymorphism (rs1801133) in 692 suicide victims and 3257 controls from a Polish adult population (WOBASZ cohort).
Statistical analysis to compare allele and genotype frequencies between cases and controls.
Exploratory analyses within suicide subgroups, including depression status (Beck Depression Inventory) and sex-specific correlations.

Main Results:

No significant difference was found in the prevalence of the MTHFR 677T allele (OR=1.02, p=0.759) or the TT genotype (OR=1.01, p=0.926) between suicide victims and controls.
An association between the TT genotype and depression (BDI score > 11) was observed in controls (OR=1.61, p=0.049), but not when comparing suicides to non-depressed controls.
Trends for correlations between the T allele dose and age at death (males) or blood ethanol concentration (females) were noted but did not reach statistical significance after Bonferroni correction.

Conclusions:

The MTHFR C677T polymorphism (rs1801133) does not appear to be a significant risk factor for completed suicide.
Further investigation into the observed sex-specific trends regarding rs1801133, age at death, and blood ethanol concentration is warranted.